Table 2 Effects of antithrombotic drugs on the results of fecal immunochemical test in colorectal neoplasms screening.
Measure | Outcome | Anti-thrombotic agents | p-value | |
|---|---|---|---|---|
Yes (n = 144) | No (n = 614) | |||
Sensitivity | CN | 38/61 (62.3%) CI (49.0–74.4%) | 122/217 (56.0%) CI (49.3–62.9%) | 0.3964 |
CRC | 11/14 (78.6%) CI (49.2–95.3%) | 35/43 (81.4%) CI (66.6–91.6%) | 0.8161 | |
CRC + AA | 21/29 (72.4%) CI (52.8–87.3%) | 75/99 (75.8%) CI (66.1–83.8%) | 0.7146 | |
NAA only | 17/32 (53.1%) CI (34.7–70.9%) | 47/118 (39.8%) CI (30.9–49.3%) | 0.1775 | |
Specificity | CN | 50/83 (60.2%) CI (48.9–70.8%) | 223/397 (56.2%) CI (51.1–61.1%) | 0.4960 |
CRC | 70/130 (53.9%) CI (44.9–62.6%) | 310/571 (54.3%) CI (50.1–58.4%) | 0.9268 | |
CRC + AA | 65/115 (56.5%) CI (47.0–65.7%) | 294/515 (57.1%) CI (52.7–61.4%) | 0.9118 | |
NAA only | 50/83 (60.2%) CI (48.9–70.8%) | 223/397 (56.2%) CI (51.1–61.1%) | 0.4960 | |
PPV | CN | 38/71 (53.5%) CI (41.3–65.5%) | 122/296 (41.2%) CI (35.6–47.1%) | 0.0604 |
CRC | 11/71 (15.5%) CI (8.0–26.0%) | 35/296 (11.8%) CI (8.4–16.1%) | 0.4018 | |
CRC + AA | 21/71 (29.6%) CI (19.3–41.6%) | 75/296 (25.3%) CI (20.5–30.7%) | 0.4654 | |
NAA only | 17/50 (34.0%) CI (21.2–48.8%) | 47/221 (21.3%) CI (16.1–27.3%) | 0.0556 | |
NPV | CN | 50/73 (68.5%) CI (56.6–78.9%) | 223/318 (70.1%) CI (64.8–75.1%) | 0.7840 |
CRC | 70/73 (95.9%) CI (88.5–99.1%) | 310/318 (97.5%) CI (95.1–98.9%) | 0.4576 | |
CRC + AA | 65/73 (89.0%) CI (79.5–95.1%) | 294/318 (92.5%) CI (89.0–95.1%) | 0.3376 | |
NAA only | 50/65 (76.9%) CI (64.8–86.5%) | 223/294 (75.9%) CI (70.5–80.6%) | 0.8545 | |
